Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors

Pharmaceutical Research

Volumn 15, Issue 10, 1998, Pages 1546-1551

  Weaver, Jean R ^a   Gan, Yuebo ^a   Au, Jessie L S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anticancer drugs; Bromodeoxyuridine; Human solid tumors; Molecular pharmacodynamic endpoints; Proliferative indices; Thymidine

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CYCLINE; DNA; DOXORUBICIN; MITOMYCIN C; PACLITAXEL;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHARMACODYNAMICS; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL DIVISION; DNA; DOXORUBICIN; HUMANS; MITOMYCIN; NEOPLASMS; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; THYMIDINE;

EID: 0031687182     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011998932047     Document Type: Article

References (28)

1. 3H]thymidine administered by injection or osmotic pump. Carcinogenesis 11:2245-2251 (1990).
2. M. Giordano, M. Danova, G. Mazzini, P. Gobbi, and A. Riccardi. Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Prognostic significance in acute nonlymphoblastic leukemia. Cancer 71:2739-2745 (1993).
3. A. R. Soames, D. Lavender, J. R. Foster, S. M. Williams, E. B. Wheeldon. Image analysis of bromodeoxyuridine (BrdU) staining for measurement of S-phase in rat and mouse liver. J. Histochem. Cytochem. 42:939-944 (1994).
4. Y. Yonemura, T. Kamata, S. Ohoyama, H. Matumoto, H. Kimura, T. Kosaka, A. Yamaguchi, K. Miwa, and I. Miyazaki. Relation of proliferative activity to survival in patients with advanced gastric cancer. Anal. Cell Path. 3:103-110 (1991).
5. N. Yousuf, G. A. Yanik, B. A. George, M. Masterson, C. M. Mazewski, L. M. White, M. A. Miller, B. C. Lampkin, and A. Raza. Comparison of two double labeling techniques to measure cell cycle kinetics in myeloid leukemias. Anticancer Res. 11:1195-1199 (1991).
6. P. Lin and D. C. Allison. Measurement of DNA content and of tritiated thymidine and bromodeoxyuridine incorporation by the same cells. J. Histochem. Cytochem. 41:1435-1439 (1993).
7. J. G. Thornton, M. Wells and W. J. Hume. Flash labelling of S-phase cells in short-term organ culture of normal and pathological human endometrium using bromodeoxyuridine and tritiated thymidine. J. Pathol. 154:321-328 (1988).
8. Y. Gan, M. G. Wientjes, D. E. Schuller and J. L.-S. Au. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56:2086-2093 (1996).
9. T. D. Schmittgen, M. G. Wientjes, R. A. Badalament, and J. L.-S. Au. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 51:3849-3856 (1991).
10. J. L.-S. Au, M. G. Wientjes, T. J. Rosol, A. Koolemans-Beynen, E. A. Goebel and, D. E. Schuller. Histocultures of patient head and neck tumors for pharmacodynamics studies. Pharm. Res. 10:1493-1499 (1993).
11. K. T. Robbins, K. M. Connors, A. M. Storniolo, C. Hanchett, and R. M. Hoffman. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch. Otolaryngol. Head Neck Surg. 120:288-292 (1994).
12. T. Kubota, N. Sasano, O. Abe, I. Nakao, E. Kawamura, T. Saito, M. Endo, K. Kimura, H. Demura, H. Sasano, H. Nagura, N. Ogawa, R. M. Hoffman, and the Chemosensitivity Study Group for the Histoculture Drug-Response Assay: Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res. 1:1537-1543 (1995).
13. T. Furukawa, T. Kubota, and R. M. Hoffman. Clinical applications of the histoculture drug response assay. Clin. Cancer Res. 1:305-311 (1995).
14. N. Weidner, D. H. Moore, B. M. Ljung, F. M. Waldman, W. H. Goodson, B. Mayall, K. Chew, and H. S. Smith. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am. J. Surg. Path. 17:987-994 (1993).
15. C. M. Quinn and N. A. Wright. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J. Pathol. 160:93-102 (1990).
16. P. A. Hall and A. L. Woods. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet. 23:505-522 (1990).
17. A. Pich, E. Margaria, and L. Chiusa. Proliferative activity is a significant prognostic factor in male breast carcinoma. Am. J. Pathol. 145:481-489 (1994).
18. J. E. Celis and A. Celis. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc. Natl. Acad. Sci. USA 82:3262-3266 (1985).
19. S. Aaltomaa, P. Lipponen, and K. Syrjanen. Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res. 12:1281-1286 (1992).
20. S. Jain, M. I. Filipe, P. A. Hall, N. Waseem, D. P. Lane, and D. A. Levison. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J. Clin. Pathol. 44:655-659 (1991).
21. R. Bravo and H. Macdonald-Bravo. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J. Cell Biol. 105:1549-1554 (1987).
22. S. M. Kang, W. H. Kim, C. W. Kim, and Y. I. Kim. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma. J. Korean Med. Sci. 9:16-20 (1994).
23. P. Galand and C. Degraef. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 22:383-392 (1989).
24. T. J. Sebo, P. C. Roche, T. E. Witzig, and P. J. Kurtin. Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis. Am. J. Clin. Pathol. 99:668-672 (1993).
25. M. D. Coltrera and A. M. Gown. PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J. Histochem. Cytochem. 39:23-30 (1991).
26. T. D. Schmittgen, J. R. Weaver, R. A. Badalament, M. G. Wientjes, E. A. Klein, D. C. Young, and J. L.-S. Au. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J. Urol. 152:1632-1636 (1994).
27. P. A. Hall, D. A. Levison, A. L. Woods, C. C. Yu, D. B. Kellock, J. A. Watkins, D. M. Barnes, C. E. Gillett, R. Camplejohn, R. Dover, N. R. Waseem, and D. P. Lane. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 162:285-294 (1990).
28. R. Bravo, R. Frank, P. A. Blundell, and H. Macdonald-Bravo. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326:515-517 (1987).